MapLight Therapeutics reports Q3 2026 loss, $463.4 M cash runway and plans Phase 3 schizophrenia trial
MapLight Therapeutics announced third‑quarter 2026 results showing a net loss of $51.6 million and diluted GAAP EPS of –$0.97. The company ended the quarter with $463.4 million in cash, cash equivalents and investments, which it says will fund operations through 2028. It confirmed start‑up activities for the ZEPHYR‑2 Phase 3 trial of ML‑007C‑MA in schizophrenia, with topline data expected in 2028, and continued enrollment in the Phase 2 VISTA trial for Alzheimer’s disease psychosis, with results expected in the second half of 2027.
Why it matters
The cash runway through 2028 gives the company financial flexibility to advance its two key clinical programs without immediate dilution risk (the company expects funds to last through 2028,). The upcoming trial readouts in 2027‑2028 are material catalysts that could drive the stock price if they meet expectations (the company highlighted these milestones in its business update, and).
Key facts
- 1Net loss for Q3 2026 was $51.6 million, up from $29.4 million in Q3 2025. rttnews.com
- 2Diluted GAAP EPS for Q3 2026 was –$0.97. tradingview.com
- 3Cash, cash equivalents and investments totaled $463.4 million as of September 30 2026. quiverquant.com
- 4The company expects its cash to fund operations through 2028. quiverquant.com
- 5Topline results from the ZEPHYR‑2 Phase 3 trial in schizophrenia are expected in 2028. quiverquant.com
- 6Topline results from the Phase 2 VISTA trial in Alzheimer’s disease psychosis are expected in the second half of 2027. quiverquant.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.